These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 17371352)

  • 1. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study.
    Diamond S; Bigal ME; Silberstein S; Loder E; Reed M; Lipton RB
    Headache; 2007 Mar; 47(3):355-63. PubMed ID: 17371352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study.
    Silberstein S; Loder E; Diamond S; Reed ML; Bigal ME; Lipton RB;
    Cephalalgia; 2007 Mar; 27(3):220-9. PubMed ID: 17263769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pivotal moment in 50 years of headache history: the first American Migraine Study.
    Tepper SJ
    Headache; 2008 May; 48(5):730-1; discussion 732. PubMed ID: 18471125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey.
    Lucas C; Géraud G; Valade D; Chautard MH; Lantéri-Minet M
    Headache; 2006 May; 46(5):715-25. PubMed ID: 16643573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and overuse of antimigraine drugs by pharmacy personnel in France: COTA survey.
    Donnet A; Lantéri-Minet M; Aucoin F; Allaf B
    Headache; 2009 Jul; 49(7):1014-21. PubMed ID: 19486362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depression and anxiety: effect on the migraine-obesity relationship.
    Tietjen GE; Peterlin BL; Brandes JL; Hafeez F; Hutchinson S; Martin VT; Dafer RM; Aurora SK; Stein MR; Herial NA; Utley C; White L; Khuder SA
    Headache; 2007 Jun; 47(6):866-75. PubMed ID: 17578537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The acute treatment of episodic and chronic migraine in the USA.
    Bigal ME; Borucho S; Serrano D; Lipton RB
    Cephalalgia; 2009 Aug; 29(8):891-7. PubMed ID: 19222509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' preference for migraine preventive therapy.
    Peres MF; Silberstein S; Moreira F; Corchs F; Vieira DS; Abraham N; Gebeline-Myers C
    Headache; 2007 Apr; 47(4):540-5. PubMed ID: 17445103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of adherence to triptans: factors of sustained vs lapsed users.
    Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
    Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment.
    Bigal ME; Serrano D; Reed M; Lipton RB
    Neurology; 2008 Aug; 71(8):559-66. PubMed ID: 18711108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and burden of headache and migraine in Germany.
    Radtke A; Neuhauser H
    Headache; 2009 Jan; 49(1):79-89. PubMed ID: 19125877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute migraine treatment: patterns of use and satisfaction in a clinical population.
    Malik SN; Hopkins M; Young WB; Silberstein SD
    Headache; 2006 May; 46(5):773-80. PubMed ID: 16643580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and patterns of medication use of migraneurs in Latin America from 12 cities in 6 countries.
    Morillo LE; Alarcon F; Aranaga N; Aulet S; Chapman E; Conterno L; Estevez E; Garcia-Pedroza F; Garrido J; Macias-Islas M; Monzillo P; Nunez L; Plascencia N; Rodriguez C; Takeuchi Y;
    Headache; 2005 Feb; 45(2):118-26. PubMed ID: 15705116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Munakata J; Hazard E; Serrano D; Klingman D; Rupnow MF; Tierce J; Reed M; Lipton RB
    Headache; 2009 Apr; 49(4):498-508. PubMed ID: 19245386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of the burden of migraine using the willingness to pay model.
    Hamelsky SW; Lipton RB; Stewart WF
    Cephalalgia; 2005 Feb; 25(2):87-100. PubMed ID: 15658945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
    Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
    Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
    J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Headache diagnosis, management and morbidity in the Singapore primary care setting: findings from a general practice survey.
    Khu JV; Siow HC; Ho KH
    Singapore Med J; 2008 Oct; 49(10):774-9. PubMed ID: 18946609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid use and dependence among persons with migraine: results of the AMPP study.
    Buse DC; Pearlman SH; Reed ML; Serrano D; Ng-Mak DS; Lipton RB
    Headache; 2012 Jan; 52(1):18-36. PubMed ID: 22268775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.